Posted by Michael Wonder on 16 Jul 2021
EMA validates BioMarin's marketing authorisation application for valoctocogene roxaparvovec to treat severe haemophilia A
15 July 2021 - Potential first gene therapy in Europe for treatment of haemophilia A.
BioMarin Pharmaceutical announced today that the EMA validated the Company's marketing authorisation application for its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe haemophilia A.
